Stock 6600 SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages SciClone Pharmaceuticals (Holdings) Limited

Equities

6600

KYG4271B1023

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:16 02/05/2024 BST 		5-day change 1st Jan Change
18.04 HKD +0.56% Intraday chart for SciClone Pharmaceuticals (Holdings) Limited +0.22% +29.60%
04-18 Sciclone Pharmaceuticals to Dispatch Privatization Documents by May 31 MT
04-01 SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SciClone Pharmaceuticals Logs 31% Increase in 2023 Profit
Sciclone Pharmaceuticals Limited Announces Executive Changes
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
SciClone Completes Patient Enrollment for Urinary Tract Infection Drug's Phase 3 Trial; Shares Rise 3%
SciClone Pharmaceuticals Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
SciClone Pharmaceuticals Limited and Menarini Establish License and Collaboration Agreement for Orserdu in China
SciClone Pharmaceuticals' Profit Jumps 18.4% in H1
SciClone Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
SciClone Pharmaceuticals Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China
SciClone Pharmaceuticals Limited Announces Commercial Launch of DANYELZA in China
SciClone Pharmaceuticals Limited commences an Equity Buyback Plan for 61,829,507 shares, representing 10% of its issued share capital, under the authorization approved on May 25, 2023.
SciClone Pharmaceuticals Limited Approves a Final Dividend for the Year Ended December 31, 2022
Sciclone Pharmaceuticals Limited Elects Ms. Pan Rongrong as an Executive Director of the Company
Sciclone Pharmaceuticals Limited Announces Retirement of SHI Cen as Non-Executive Director
Sciclone Pharmaceuticals Limited Declares Final Dividend for the Year Ended December 31, 2022, Payable on 28 June 2023
SciClone Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Sciclone Pharmaceuticals Limited Announces Nmpa Approval of Ind Application for Vaborem
SciClone Pharmaceuticals Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration
SciClone Pharmaceuticals Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6600 Stock
  4. News SciClone Pharmaceuticals (Holdings) Limited
  5. Other languages